Dr. Enriqueta Felip
Claim this profileGSK Investigational Site
Expert in Lung Cancer
Studies Non-Small Cell Lung Cancer
25 reported clinical trials
35 drugs studied
Area of expertise
1Lung Cancer
Global LeaderStage IV
Stage III
PD-L1 positive
2Non-Small Cell Lung Cancer
Stage IV
Stage III
PD-L1 positive
Clinical Trials Enriqueta Felip is currently running
BI 764532
for Small Cell Lung Cancer
This study is open to adults with small cell lung cancer and other neuroendocrine cancers that are positive for the tumour marker delta-like 3 (DLL3). The study is in people with advanced cancer for whom previous treatment was not successful or no standard treatment exists. The purpose of this study is to find out the highest dose of BI 764532 and the best treatment schedule that people can tolerate. BI 764532 is an antibody-like molecule (DLL3/CD3 bispecific) that may help the immune system fight cancer. In this study, BI 764532 is given to people for the first time. That means no clinical data are available for BI 764532. Participants get BI 764532 either weekly or once every 3 weeks. If there is benefit for the participants and if they can tolerate it, the treatment is given for a maximum of 3 years. During this time, participants visit the study site about 20 times depending on the response to the treatment. Doctors record any unwanted effects and regularly check the general health of the participants.
Recruiting1 award Phase 110 criteria
MCLA-129
for Non-Small Cell Lung Cancer
This trial tests a new drug, MCLA-129, on its own in patients with advanced cancers who did not respond to previous treatments. The study will adjust doses to find the safest and most effective amount.
Recruiting1 award Phase 1 & 217 criteria
More about Enriqueta Felip
Clinical Trial Related6 years of experience running clinical trials · Led 25 trials as a Principal Investigator · 8 Active Clinical TrialsTreatments Enriqueta Felip has experience with
- Pembrolizumab
- Dostarlimab
- ATL001
- Niraparib
- Docetaxel
- Cobolimab
Breakdown of trials Enriqueta Felip has run
Lung Cancer
- Pilot Immunotherapy Study With Letetresgene Autoleucel (Lete-cel, GSK3377794)T-cells in New York Esophageal Squamous Cell Carcinoma-1 (NY-ESO-1)/ LAGE-1a-positive Advanced Non-small Cell Lung Cancer (NSCLC) Either Alone or in Combination With Pembrolizumab
- ABC-lung: Atezolizumab, Bevacizumab and Chemotherapy in EGFR-mutant Non-small Cell Lung Carcinoma
- MCLA-129 for Non-Small Cell Lung Cancer
Non-Small Cell Lung Cancer
Cancer
- Pilot Immunotherapy Study With Letetresgene Autoleucel (Lete-cel, GSK3377794)T-cells in New York Esophageal Squamous Cell Carcinoma-1 (NY-ESO-1)/ LAGE-1a-positive Advanced Non-small Cell Lung Cancer (NSCLC) Either Alone or in Combination With Pembrolizumab
- BI 764532 for Small Cell Lung Cancer
- Novel Drug Regimens for Lung Cancer
Tumors
- Pilot Immunotherapy Study With Letetresgene Autoleucel (Lete-cel, GSK3377794)T-cells in New York Esophageal Squamous Cell Carcinoma-1 (NY-ESO-1)/ LAGE-1a-positive Advanced Non-small Cell Lung Cancer (NSCLC) Either Alone or in Combination With Pembrolizumab
- Novel Drug Regimens for Lung Cancer
- Adoptive Cell Therapy for Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Enriqueta Felip specialize in?
Enriqueta Felip focuses on Lung Cancer and Non-Small Cell Lung Cancer. In particular, much of their work with Lung Cancer has involved Stage IV patients, or patients who are Stage III.
Is Enriqueta Felip currently recruiting for clinical trials?
Yes, Enriqueta Felip is currently recruiting for 8 clinical trials in Barcelona Catalonia. If you're interested in participating, you should apply.
Are there any treatments that Enriqueta Felip has studied deeply?
Yes, Enriqueta Felip has studied treatments such as Pembrolizumab, Dostarlimab, ATL001.
What is the best way to schedule an appointment with Enriqueta Felip?
Apply for one of the trials that Enriqueta Felip is conducting.
What is the office address of Enriqueta Felip?
The office of Enriqueta Felip is located at: Vall d'Hebron Institute of Oncology, Barcelona, Catalonia 08035 Spain. This is the address for their practice at the Vall d'Hebron Institute of Oncology.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.